• Explore /
  • Poster
  • / Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).

Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).

Abstract Video & Slides Poster

Authors

null

Sagar Lonial

Emory University Hospital, Winship Cancer Institute, Atlanta, GA

Sagar Lonial , Hans Chulhee Lee , Ashraf Badros , Suzanne Trudel , Ajay K. Nooka , Ajai Chari , Al-Ola A. Abdallah , Natalie Scott Callander , Douglas Weston Sborov , Attaya Suvannasankha , Katja Weisel , Peter Michael Voorhees , Axel Hoos , Eric Zhi , January Baron , Trisha Piontek , Roxanne C. Jewell , Joanna Opalinska , Ira Gupta , Adam D. Cohen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03525678

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8536)

DOI

10.1200/JCO.2020.38.15_suppl.8536

Abstract #

8536

Poster Bd #

436

Abstract Disclosures

Similar Posters

First Author: Evangelos Terpos

First Author: Dan T. Vogl

First Author: Yi Lin

First Author: Malin Hultcrantz